Please ensure Javascript is enabled for purposes of website accessibility

3 Great Stocks That Are Still Ridiculously Cheap Right Now

By Keith Speights – Apr 16, 2020 at 7:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And two of the three offer nice dividends, too.

After one of the fastest meltdowns ever, the stock market has rebounded quite a bit. There's even an argument to be made about whether we really still have a bear market. 

But despite the bounce for many stocks, most of them still haven't regained their previous highs. Plenty of bargains can be found. Here are three great stocks that are still ridiculously cheap right now.

Tiny shopping cart with hundred dollar bills in it

Image source: Getty Images.

1. AbbVie

AbbVie (ABBV -5.96%) shares trade at a little over eight times expected earnings. That makes AbbVie one of the cheapest big pharma stocks on the market. There's one word that explains why the stock is so inexpensive: Humira.

Since AbbVie was spun off from Abbott Labs in 2013 (and even before then), its management team has been bracing for the day when Humira would lose patent exclusivity. That day has already come in Europe and is on the way in the U.S. in 2023. The problem for AbbVie is that it's highly dependent on its top-selling drug.

If AbbVie didn't have a plan to deal with the sales declines for Humira, the stock would be a value trap instead of a value play. But AbbVie does have a plan. Its lineup includes several drugs that will fuel revenue growth for years to come, with cancer drugs Imbruvica and Venclexta and new immunology drugs Rinvoq and Skyrizi at the top of the list. The company also awaits the closing of its acquisition of Allergan, a deal that will significantly reduce its dependence on Humira.

AbbVie probably won't deliver tremendous growth over the next several years in the aftermath of Humira's loss of exclusivity. However, it doesn't have to do so to be able to generate solid total returns for long-term investors. AbbVie's dividend yield stands at close to 5.9%. The company ranks as a Dividend Aristocrat with 47 consecutive years of dividend increases and places a high priority on its dividend program.

2. Berkshire Hathaway

Berkshire Hathaway (BRK.A -0.06%) (BRK.B -0.95%) hasn't been this cheap in years. The stock trades at only a little over its book value, less than six times trailing-12-month earnings, and around 18 times expected earnings. Berkshire CEO Warren Buffett might not be a big fan of any of these valuation metrics, but he undoubtedly likes the stock's current valuation considering that the company was buying back shares last year when the stock was priced well above current levels.

Like many companies, Berkshire Hathaway's near-term prospects will be impacted by the COVID-19 outbreak. Several of its retail businesses, in particular, could experience revenue and earnings declines. However, Berkshire also owns businesses that aren't likely to be affected much by the coronavirus pandemic, notably including its insurance operations.

But the negative impact on Berkshire from COVID-19 will only be temporary. The company's subsidiaries and its massive investment portfolio will almost certainly recover quickly once the crisis is over.

Remember, too, that Buffett is a master at making smart investments during market downturns. And he has a lot of cash at his disposal to use in investing. Berkshire's cash stockpile, including cash and equivalents, totaled $125 billion at the end of 2019.

3. Bristol Myers Squibb

Bristol Myers Squibb (BMY -0.86%) is another big pharma stock that, like AbbVie, appears to be attractively priced right now. Its shares trade at around 9.4 times expected earnings. However, unlike AbbVie, BMS should deliver strong growth over the next several years.

Wall Street analysts predict that the big drugmaker will be able to increase its earnings by more than 18% annually on average over the next five years. This estimate seems achievable considering BMS' solid product lineup and promising pipeline candidates.

Two of the top five best-selling drugs in the world over the next few years belong to BMS -- blood thinner Eliquis and cancer immunotherapy Opdivo. The company also has other blockbuster drugs with fast-growing sales, including Abraxane, Orencia, Pomalyst, and Revlimid. New products such as blood disease drug Reblozyl and multiple sclerosis drug Zeposia are also likely to be huge winners.

Bristol Myers Squibb also offers an appealing dividend with a current yield of a little over 3%. For investors looking for value, growth, and income, it's hard to beat BMS.

Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short June 2020 $205 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$71.09 (-0.86%) $0.62
AbbVie Inc. Stock Quote
AbbVie Inc.
$134.21 (-5.96%) $-8.51
Berkshire Hathaway Inc. Stock Quote
Berkshire Hathaway Inc.
$406,470.00 (-0.06%) $-230.00
Berkshire Hathaway Inc. Stock Quote
Berkshire Hathaway Inc.
$267.02 (-0.95%) $-2.56
Allergan plc Stock Quote
Allergan plc
Abbott Laboratories Stock Quote
Abbott Laboratories
$96.76 (-1.56%) $-1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.